Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms
Marie Ranson(University of Wollongong), Andrew Katsifis(Australian Nuclear Science and Technology Organisation), Rachael Shepherd(Australian Nuclear Science and Technology Organisation), Paula Berghofer(Australian Nuclear Science and Technology Organisation), Kara L. Vine(University of Wollongong), Ivan Greguric(Australian Nuclear Science and Technology Organisation)
Cited by 4
Related Papers
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
|Journal of Controlled Release|2018|297
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
|Anti-Cancer Agents in Medicinal Chemistry|2009|269
Biopolymers for Antitumor Implantable Drug Delivery Systems: Recent Advances and Future Outlook
|Advanced Materials|2018|217
In vitro cytotoxicity evaluation of some substituted isatin derivatives
|Bioorganic & Medicinal Chemistry|2006|193
An Investigation into the Cytotoxicity and Mode of Action of Some Novel <i>N</i>-Alkyl-Substituted Isatins
|Journal of Medicinal Chemistry|2007|150